Linezolid

Linezolid is an oxazolidinone antibiotic used to treat serious bacterial infections.

• Complicated skin and skin structure infections: effective against Gram‑positive pathogens, including MRSA, reducing infection severity.
• Community‑acquired bacterial pneumonia: provides coverage for typical and atypical organisms, improving respiratory outcomes.
• Nosocomial pneumonia: active against resistant strains, aiding recovery in hospital‑acquired lung infections.
• Infections caused by methicillin‑resistant Staphylococcus aureus (MRSA): eradicates MRSA, preventing progression.
• Infections caused by vancomycin‑resistant Enterococcus (VRE): offers an alternative treatment option for VRE infections.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex required for translation. This blocks the early stage of peptide chain assembly, producing a bacteriostatic effect against susceptible Gram‑positive organisms, including resistant strains such as MRSA and VRE. By targeting a site distinct from other antibiotic classes, linezolid retains activity where other agents fail, making it valuable for multidrug‑resistant infections.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools.
• Headache: transient cranial discomfort.
• Vomiting: occasional emesis.
• Rash: mild skin eruption.
• Thrombocytopenia: reduced platelet count, usually dose‑related.

Serious or Rare Side Effects

• Peripheral neuropathy: sensory nerve damage with prolonged use.
• Optic neuropathy: vision changes, potentially irreversible.
• Myelosuppression: severe bone‑marrow suppression leading to anemia or leukopenia.
• Lactic acidosis: metabolic acidosis with high lactate.
• Serotonin syndrome: risk when combined with serotonergic agents.
• Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.

When prescribing linezolid, clinicians should consider several safety and handling precautions.

• Hematologic monitoring: check complete blood count regularly for thrombocytopenia or anemia.
• Renal and hepatic function: assess baseline and monitor during therapy, especially in patients with impairment.
• Duration of therapy: limit to recommended course to reduce risk of neuropathy and myelosuppression.
• Drug interactions: avoid concomitant serotonergic drugs to prevent serotonin syndrome.
• Pregnancy and lactation: use only if benefit outweighs risk; category B.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several medication classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors (MAOIs): may precipitate serotonin syndrome.
• Tyramine‑containing foods and sympathomimetic agents: risk of hypertensive crisis when combined with MAOIs.

Moderate Interactions (Monitor Closely)

• Rifampicin: induces hepatic enzymes, reducing linezolid plasma levels.
• Anticoagulants (warfarin): may increase INR, requiring dose adjustment.
• NSAIDs: additive risk of bleeding when thrombocytopenia occurs.
• Anticonvulsants (carbamazepine, phenytoin): may lower linezolid concentrations.